StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$31.74+1.76 (+5.87%)

Close on Nov 18, 2026Market cap $373.06MP/E –Yield –

Surrozen net income

Net income is the profit left for shareholders after every expense, interest and tax.

Surrozen's net income for the twelve months ending Jun 30, 2026 was -$332.13M. For fiscal 2025 it was -$242.03M. The highest annual figure on record is -$32.72M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$242.03M–
FY2024Dec 31, 2024-$63.56M–
FY2023Dec 31, 2023-$43.04M–
FY2022Dec 31, 2022-$36.00M–
FY2021Dec 31, 2021-$54.65M–
FY2020Dec 31, 2020-$32.72M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$50.18M+26.2%
Q1 FY2026Mar 31, 2026-$127.51M–
Q4 FY2025Dec 31, 2025-$183.16M–
Q3 FY2025Sep 30, 2025-$71.64M–
Q2 FY2025Jun 30, 2025$39.75M–
Q1 FY2025Mar 31, 2025-$26.97M–
Q4 FY2024Dec 31, 2024-$28.04M–
Q3 FY2024Sep 30, 2024-$1.43M–
Q4 FY2023Dec 31, 2023-$8.91M–
Q3 FY2023Sep 30, 2023-$10.45M–
Q2 FY2023Jun 30, 2023-$9.39M–
Q1 FY2023Mar 31, 2023-$14.30M–
Q4 FY2022Dec 31, 2022-$775.00K–
Q3 FY2022Sep 30, 2022-$13.36M–
Q2 FY2022Jun 30, 2022-$13.93M–
Q1 FY2022Mar 31, 2022-$7.95M–
Q4 FY2021Dec 31, 2021-$14.95M–
Q3 FY2021Sep 30, 2021-$14.02M–
Q2 FY2021Jun 30, 2021-$12.65M–
Q1 FY2021Mar 31, 2021-$13.02M–
Q4 FY2020Dec 31, 2020-$10.83M–
Q3 FY2020Sep 30, 2020-$8.64M–

More Surrozen figures

See a number that looks wrong?